<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="human immunodeficiency virus (HIV) infection.4 Lopinavir has antiviral activity, while" exact="ritonavir" post="acts as a lopinavir enhancer, increasing its plasma concentrations"/>
 <result pre="infection.4 Lopinavir has antiviral activity, while ritonavir acts as a" exact="lopinavir" post="enhancer, increasing its plasma concentrations by inhibiting CYP3A4. A"/>
 <result pre="rate of interaction was inhaled budesonide (11.41%, nâ€¯=â€¯42), followed by" exact="simvastatin" post="(9.51%, nâ€¯=â€¯35) and atorvastatin (7.07%, nâ€¯=â€¯26). The rates of"/>
 <result pre="inhaled budesonide (11.41%, nâ€¯=â€¯42), followed by simvastatin (9.51%, nâ€¯=â€¯35) and" exact="atorvastatin" post="(7.07%, nâ€¯=â€¯26). The rates of interactions by drug, together"/>
 <result pre="(ATC) Risk level N (%) Mechanism Effect Recommendationa Antiemetics Â" exact="Domperidone" post="X 3 (0.82) CYP3A4 inhibition. QT prolongation â†‘ Dc."/>
 <result pre="Cardiovascular toxicity risk, ventricular arrhythmia (TdP) Contraindicated. Consider change to" exact="metoclopramide" post="Antidiabetic Â Glibenclamide C 2 (0.54) CYP3A4 and 2D6"/>
 <result pre="ventricular arrhythmia (TdP) Contraindicated. Consider change to metoclopramide Antidiabetic Â" exact="Glibenclamide" post="C 2 (0.54) CYP3A4 and 2D6 inhibitionb â†‘ Dc."/>
 <result pre="â†‘ Dc. Risk of hypoglycaemia Reduce dosage. Monitor glucose. Â" exact="Gliclazide" post="C 1 (0.27) Induction of CYP2C9 and 2C19b â†&quot;"/>
 <result pre="â†‘ Dc. Risk of hypoglycaemia Reduce dosage. Monitor glucose. Â" exact="Canagliflozin" post="D 1 (0.27) Induction of UGT1A9 and 2B4 â†&quot;"/>
 <result pre="to 200â€¯mg or 300â€¯mg. Monitor glucose. If GFRâ€¯ Anticoagulants Â" exact="Apixaban" post="D 5 (1.36) CYP3A4 inhibition. P-glycoprotein inhibition â†‘ Dc."/>
 <result pre="Risk of bleeding Change to LMWH at therapeutic doses. Â" exact="Rivaroxaban" post="X 3 (0.82) Contraindicated. Change to LMWH at therapeutic"/>
 <result pre="to 30â€¯mg or switch to LMWH at therapeutic doses. Â" exact="Acenocoumarol" post="C 11 (2.99) CYP2C9 induction â†&quot; Dc. Thrombotic risk"/>
 <result pre="Thrombotic risk Change to LMWH at therapeutic doses. Antiplatelet Â" exact="Clopidogrel" post="C 15 (4.08) Inhibition of CYP3A4, (2B6, 2C9 and"/>
 <result pre="Switch to ASA (monotherapy), switch to prasugrel (dual therapy) Â" exact="Ticagrelor" post="X 2 (0.54) CYP3A4 inhibition Dc. Risk of bleeding"/>
 <result pre="AV block Reduce dose 50%. Monitor BP and ECG. Â" exact="Nifedipine" post="D 5 (1.36) Reduce dosage. Monitor BP and ECG."/>
 <result pre="D 5 (1.36) Reduce dosage. Monitor BP and ECG. Â" exact="Manidipine" post="D 3 (0.82) Reduce dosage. Monitor BP and ECG."/>
 <result pre="D 3 (0.82) Reduce dosage. Monitor BP and ECG. Â" exact="Lercanidipine" post="X 2 (0.54) Contraindicated. Change to amlodipine with a"/>
 <result pre="amlodipine with a 50% dose reduction. Other cardiovascular drugs Â" exact="Digoxin" post="D 2 (0.54) P-glycoprotein inhibition. Prolonged PR â†‘ Dc."/>
 <result pre="poisoning Reduce dose between 30%âˆ’50% or reduce frequency. Monitor for" exact="digoxin" post="levels. Â Ivabradine X 1 (0.27) CYP3A4 inhibition â†‘"/>
 <result pre="between 30%âˆ’50% or reduce frequency. Monitor for digoxin levels. Â" exact="Ivabradine" post="X 1 (0.27) CYP3A4 inhibition â†‘ Dc. Bradycardia risk"/>
 <result pre="1 (0.27) CYP3A4 inhibition â†‘ Dc. Bradycardia risk Contraindicated. Â" exact="Ranolazine" post="(C01EB18) X 2 (0.54) CYP3A4 inhibition. QT prolongation â†‘"/>
 <result pre="Risk of bradycardia, hypotension, ventricular arrhythmia (TdP) Contraindicated. Antiarrhythmics Â" exact="Amiodarone" post="X 5 (1.36) CYP3A4 inhibition. QT prolongation â†‘ Dc."/>
 <result pre="Dc. Risk of ventricular arrhythmia Contraindicated. Close monitoring, ECG Â" exact="Flecainide" post="X 1 (0.27) Â Propafenone X 3 (0.82) CYP3A4"/>
 <result pre="Contraindicated. Close monitoring, ECG Â Flecainide X 1 (0.27) Â" exact="Propafenone" post="X 3 (0.82) CYP3A4 and 2D6 inhibitionb Close monitoring,"/>
 <result pre="bradycardia and increased negative inotropic effect Reduce dosage. ECG. Â" exact="Verapamil" post="D 6 (1.63) Lipid-lowering drugs (statins) Â Atorvastatin D"/>
 <result pre="of liver toxicity and rhabdomyolysis Maximum dose 20 mg Â" exact="Lovastatin" post="X 1 (0.27) Contraindicated. Switch to pravastatin or pitavastatin"/>
 <result pre="20 mg Â Lovastatin X 1 (0.27) Contraindicated. Switch to" exact="pravastatin" post="or pitavastatin Â Simvastatin X 35 (9.51) Contraindicated. Switch"/>
 <result pre="Â Lovastatin X 1 (0.27) Contraindicated. Switch to pravastatin or" exact="pitavastatin" post="Â Simvastatin X 35 (9.51) Contraindicated. Switch to pravastatin"/>
 <result pre="X 1 (0.27) Contraindicated. Switch to pravastatin or pitavastatin Â" exact="Simvastatin" post="X 35 (9.51) Contraindicated. Switch to pravastatin or pitavastatin"/>
 <result pre="or pitavastatin Â Simvastatin X 35 (9.51) Contraindicated. Switch to" exact="pravastatin" post="or pitavastatin Â Rosuvastatin D 3 (0.82) BCRP and"/>
 <result pre="Â Simvastatin X 35 (9.51) Contraindicated. Switch to pravastatin or" exact="pitavastatin" post="Â Rosuvastatin D 3 (0.82) BCRP and OATP1B1 transporter"/>
 <result pre="and OATP1B1 transporter inhibition Maximum dose 10 mg Urological Â" exact="Tamsulosin" post="X 18 (4.89) CYP3A4 and 2D6 inhibitionb â†‘ Dc."/>
 <result pre="anticholinergic toxicity Maximum dose 5â€¯mg/day. Monitor anticholinergic effects Corticosteroids Â" exact="Methylprednisolone" post="D 23 (6.25) CYP3A4 inhibition â†‘ Dc. Risk of"/>
 <result pre="inhibition â†‘ Dc. Risk of Cushing's syndrome Reduce dose Â" exact="Prednisone" post="C 5 (1.36) Â Dexamethasone D 1 (0.27) CYP3A4"/>
 <result pre="(LPV/r) CYP3A4 induction (dexamethasone) â†&quot; LPV/r. Decreased efficacy Antimicrobial Â" exact="Clarithromycin" post="D 6 (1.63) CYP3A4 inhibition. QT prolongation â†‘ Dc."/>
 <result pre="If GFR 30âˆ’60â€¯ml/min, reduce dose to 500â€¯mg/24â€¯h If GFRâ€¯ Â" exact="Metronidazole" post="X 1 (0.27) LPV/r oral solution contains alcohol. Disulfiram"/>
 <result pre="Â Metronidazole X 1 (0.27) LPV/r oral solution contains alcohol." exact="Disulfiram" post="reaction risk Contraindicated with the oral solution. No tablets"/>
 <result pre="risk Contraindicated with the oral solution. No tablets Antioestrogens Â" exact="Tamoxifen" post="D 3 (0.82) CYP3A4 and 2D6 inhibitionb â†&quot; AMC."/>
 <result pre="D 3 (0.82) CYP3A4 and 2D6 inhibitionb â†&quot; AMC. Decreased" exact="oestrogen" post="modulating effect Muscle relaxants Â Fentanyl iv D 4"/>
 <result pre="inhibitionb â†&quot; AMC. Decreased oestrogen modulating effect Muscle relaxants Â" exact="Fentanyl" post="iv D 4 (1.09) CYP3A4 inhibition â†‘ Dc. Risk"/>
 <result pre="depression Reduce dose to 25âˆ’50â€¯mcg/h. Monitor pain (ANI, NOL) Â" exact="Midazolam" post="iv D 24 (6.52) â†‘ Dc. Risk of respiratory"/>
 <result pre="exceedâ€¯&amp;gt;â€¯25â€¯mg/kg/h). Monitor depth of sedation (BIS). Opioid pain relievers Â" exact="Fentanyl" post="oral/patch D 2 (0.54) CYP3A4 inhibition â†‘ Dc. Risk"/>
 <result pre="Dc. Risk of sedation and respiratory depression. Reduce dose Â" exact="Oxycodone" post="D 1 (0.27) CYP3A4 and 2D6 inhibitionb â†‘ Dc."/>
 <result pre="â†‘ Dc. Risk of sedation and respiratory depression. Anticonvulsants Â" exact="Carbamazepine" post="D 1 (0.27) CYP3A4 inhibition (LPV/r) â†‘ Dc. CNS"/>
 <result pre="dose. CYP3A4 (carbamazepine) induction â†&quot; LPV/r. Decreased antiviral effect Â" exact="Phenytoin" post="D 1 (0.27) CYP2C9 and 2C19 induction (LPV/r) â†&quot;"/>
 <result pre="2 times a day and consider increasing the dose. Monitor" exact="phenytoin" post="levels and adjust dose CYP3A (phenytoin) induction â†&quot; LPV/r."/>
 <result pre="dose CYP3A (phenytoin) induction â†&quot; LPV/r. Decreased antiviral effect Â" exact="Clonazepam" post="D 5 (1.36) CYP3A4 inhibition â†‘ Dc. Risk of"/>
 <result pre="Dc. Risk of sedation and drowsiness. Reduce dose Hypnotic/sedatives Â" exact="Alprazolam" post="D 10 (2.72) Inhibition of CYP3A4 and P-glycoprotein â†‘"/>
 <result pre="respiratory depression. Start low dose and increase as needed. Â" exact="Clorazepate" post="C 3 (0.82) Reduce dosage. Â Diazepam D 15"/>
 <result pre="as needed. Â Clorazepate C 3 (0.82) Reduce dosage. Â" exact="Diazepam" post="D 15 (4.08) CYP3A4 and C219 inhibitionb Avoid. Reduce"/>
 <result pre="(4.08) CYP3A4 and C219 inhibitionb Avoid. Reduce dosage. Neuroleptics Â" exact="Haloperidol" post="D 8 (2.17) CYP3A4, 2D6b inhibition and glucuronidation (UGT2B7â€¯&amp;gt;â€¯1A4"/>
 <result pre="in the elderly. Reduce dosage. Monitor CNS effects. ECG. Â" exact="Quetiapine" post="D 11 (2.99) CYP3A4 and 2D6 inhibitionb. QT prolongation"/>
 <result pre="Cardiovascular toxicity risk: tachycardia and ventricular arrhythmia (TdP) Contraindicated. Consider" exact="salbutamol" post="Antihistamines Â Ebastine D 1 (0.27) CYP3A4 inhibition â†‘"/>
 <result pre="of drowsiness, xerostomia, and headache Reduce dosage. Consider dexchlorpheniramine ASA:" exact="acetylsalicylic acid;" post="ANI: analgesia nociception index; AV: atrioventricular; Dc: drug concentration;"/>
 <result pre="slow cardiac repolarization and prolong the QT interval.5 In addition," exact="hydroxychloroquine" post="and azithromycin, drugs currently used in combination with LVP/r"/>
 <result pre="associated with developing potential interactions with LPV/r in our study." exact="Simvastatin" post="and atorvastatin were 2 of the drugs with the"/>
 <result pre="developing potential interactions with LPV/r in our study. Simvastatin and" exact="atorvastatin" post="were 2 of the drugs with the highest rate"/>
 <result pre="20 April 2020]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCovChina/documentos.htm. 2YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirusâ€&quot;a possible reference"/>
</results>
